Sage Therapeutics, Inc.

Ownership Transactions Reported by 18 Insiders

Symbol
SAGE on Nasdaq
Industry
Pharmaceutical Preparations
Location
55 Cambridge Parkway, Cambridge, MA

There are no Buy or Sell transactions made by insiders since 4/23/2024

Sage Therapeutics, Inc. executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
Iguchi Kimi CFO & Treasurer $729K Aug 5, 2024
Barry E. Greene President and CEO, Director $692K Apr 10, 2025
Christopher Benecchi Chief Operating Officer $335K Apr 10, 2025
Laura Gault Chief Medical Officer $249K Feb 13, 2025
Cook Anne Marie SVP, GC & Secretary $215K Aug 5, 2024
Gregory L. Shiferman Senior Vice President, General Counsel and Secretary $214K Apr 10, 2025
Michael C. Quirk Chief Scientific Officer and Interim Head of R&D $211K Apr 10, 2025
Albert Robichaud Chief Scientific Officer $198K Feb 13, 2023
Jeffrey M. Jonas Director $174K Jun 10, 2024
Stephen Kanes Chief Medical Officer $18.3K Oct 19, 2021
Elizabeth Barrett Director $4.08K Jun 10, 2024
Kevin P. Starr Director Jun 15, 2023
Geno Germano Director Jun 10, 2024
George Golumbeski Director Jan 3, 2025
Jessica Federer Director Jun 10, 2024
Michael F. Cola Director Jun 10, 2024
James M. Frates Director Jan 3, 2025
Steven M. Paul Director Jan 3, 2024

Recent Insider Transactions by Companies or Individuals for Sage Therapeutics, Inc.

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.